California researchers have conducted a study on the severity of COVID-19 among adult smokers. Titled "Smoking and SARS-CoV-2 infection risk and disease severity among adults in the California Healthcare System," the study consisted of a retrospective cohort study of over 2.4 million adults in a large healthcare system. The aim was to identify any potential links between smoking and the severity of SARS-CoV-2 (COVID-19) infection.
According to current research, smoking appears to be a protective factor against COVID-19 infection, consistent with previous findings. However, it often leads to more severe symptoms in those who do become infected. The largest study conducted in the United States to date on smoking and COVID-19 has found that current and past smokers have a lower risk of contracting SARS-CoV-2 compared to non-smokers. However, a history of smoking is strongly associated with an increased risk of severe COVID-19.
A study titled "Smoking and COVID-19 outcomes: An observational and Mendelian randomisation study using the UK Biobank cohort" combines observational and Mendelian randomization analysis to provide a better understanding of the relationship between smoking and COVID-19. The study aims to shed light on this connection.
A research team analyzed primary healthcare records, COVID-19 test results, hospitalization data, and death certificates from 420,000 participants in the UK biobank from January to August 2020, in order to look for a correlation between smoking and the severity of COVID-19 infection.
A total of 421,000 eligible participants were included in the study, with 1,649 confirmed infections, 968 COVID-19-related hospitalizations, and 444 COVID-19-related deaths. Current smokers were found to have a higher risk of hospitalization and death compared to non-smokers. Magnetic resonance imaging analysis of 280,000 white British participants revealed a genetic predisposition towards smoking that was associated with a higher risk of infection and hospitalization. Study authors reported that the predicted risk for all outcomes increased with greater daily smoking frequency based on genetic prediction.
After analyzing the data, the research group concluded that nicotine, which has been considered a protective factor against COVID-19, may actually worsen the severity of the infection. On the other hand, numerous studies have reported that smoking, specifically the intake of nicotine, can act as a protective barrier against contracting the virus.
According to data from the Centers for Disease Control and Prevention (CDC), only 1.3% of analyzed COVID-19 cases were smokers, despite the fact that the adult smoking rate in the United States is 13.7%. Similarly, a commentary report on Chinese data published in the European Journal of Internal Medicine states that "active smoking does not appear to have a significant correlation with an increased risk of COVID-19 progression to a severe illness.
Statement:
This article is compiled from third-party information and is intended for the purpose of industry exchange and learning.
Translation: This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The article's translation is only intended for industry communication and research.
Due to limitations in the translator's proficiency, the translated article may not fully convey the intended meaning of the original text. Please refer to the original article for accuracy.
2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macao, Taiwan, and foreign-related statements and positions.
The compilation of information belongs to the original media and author, and if there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
